Table 2 Exploratory endpoints
Placebo | Sildenafil | |||||
|---|---|---|---|---|---|---|
Baseline | Follow Up | p-value | Baseline | Follow up | p-value | |
HR (BPM) | 69 (9) | 68 (7) | 0.49 | 84 (12) | 85 (12) | 0.58 |
Cardiac magnetic resonance imaging derived parameters | ||||||
RV SV (mL) | 68 (19) | 68 (18) | 0.96 | 57 (19) | 58 (22) | 0.84 |
CO (l/min) | 4.53 (0.94) | 4.54 (1.14) | 0.97 | 4.71 (1.44) | 4.76 (1.34) | 0.89 |
RV EDV (mL) | 222 (19) | 222 (12) | 1.00 | 193 (73) | 184 (76) | 0.05 |
RV ESV (mL) | 152 (18) | 153 (15) | 0.77 | 135 (62) | 125 (62) | 0.04 |
RV EF (%) | 32 (8) | 31 (8) | 0.50 | 31 (8) | 34 (9) | 0.14 |
MPLS (%) | − 12.3 (3.4) | − 13.1 (3.4) | 0.17 | − 12.9 (4.1) | − 13.1 (4.0) | 0.89 |
Right heart catheterization derived parameters | ||||||
mPCWP (mmHg) | 11.1 (4.5) | 12.4 (4.4) | 0.02 | 17.0 (4.9) | 15.0 (3.7) | 0.14 |
PAPd (mmHg) | 15.7 (3.2) | 17.6 (2.6) | 0.31 | 17.1 (3.1) | 17.0 (6.7) | 0.96 |
PAPs (mmHg) | 47.0 (6.6) | 47.4 (4.8) | 0.92 | 47.0 (7.7) | 42.9 (5.3) | 0.21 |
mPAP (mmHg) | 27.0 (2.9) | 27.6 (2.4) | 0.66 | 27.3 (3.7) | 25.3 (3.4) | 0.30 |
PVR (wood) | 3.5 (1.0) | 3.5 (1.4) | 0.86 | 2.3 (1.0) | 2.0 (1) | 0.43 |
SVO2 (%) | 62.6 (6.7) | 64.4 (8.5) | 0.29 | 65.9 (8.5) | 65.2 (7.3) | 0.67 |
Trans thoracic echocardiography derived parameters | ||||||
RV/LV | 1.10 (0.05) | 1.12 (0.19) | 0.39 | 1.12 (0.11) | 1.08 (0.21) | 0.47 |
RV FAC (%) | 0.30 (0.14) | 0.30 (0.11) | 0.98 | 0.34 (0.15) | 0.37 (0.14) | 0.28 |
TAPSE (cm) | 1.79 (0.44) | 1.78 (0.56) | 0.86 | 1.69 (0.36) | 1.79 (0.44) | 0.33 |
PAAT (ms) | 64 (12) | 54 (12) | 0.02 | 61 (8) | 64 (13) | 0.40 |
TI (mmHg) | 36 (8) | 36 (10) | 0.81 | 33 (8) | 31 (3) | 0.52 |